Matricelf Continues Clinical Execution with Patient Enrollment Preparation Following GLP Safety Success and GMP Manufacturing Milestones

Trial StartPositive

AI Analysis

Summary

Matricelf Ltd. has completed GLP safety studies and achieved GMP manufacturing milestones, enabling patient enrollment preparation for its planned first-in-human spinal cord injury study with approval from Loewenstein Medical Center.

Clinical Trial Data

Phase

Phase_1

Outcome Details

GLP safety study completed successfully; GMP manufacturing milestones achieved; patient enrollment preparation underway for first-in-human spinal cord injury study

Importance:6/10

Sentiment:

0.70

regenerative medicineautologousspinal cord injuryGLP safetyGMP manufacturingclinical trial preparation

Related Companies

$MTLF

Read the original article

Published by PR Newswire Biotech on July 9, 2026 11:00 AM

Read Original